Rectal Cancer
Conditions
Keywords
neochemotherapy, CRM
Brief summary
Neoadjuvant 5-Fu based chemoradiation followed by surgery is a standard treatment for locally advanced rectal cancer. However, radiation-related side effects could not be neglected. But this multimodality strategy failed to improve survival. Neoadjuvant chemotherapy alone may be an alternative strategy to minimize treatment-related toxicities without compromising the oncology outcome. Thus, patients with MRI-defined CRM-positive rectal cancer will receive 6 cycles of neoadjuvant treatment with FOLFOXIRI followed by surgery. The purpose of the study is to evaluate the efficacy of FOLFOXIRI alone as neoadjuvant treatment in treating patients with locally advanced rectal cancer.
Detailed description
Preoperative chemoradiotherapy has been considered for years the standard treatment to patients with locally advanced rectal cancer. However, this multi-modality treatment has been questioned since more evidences suggested that radiotherapy may not be a necessary component of this treatment, and by omitting radiotherapy it have the advantage of reducing acute and late treatment-related toxicities. Given the high anti-tumor of systemic chemotherapy alone, any patients with CRM involvement could be theoretically deemed candidate for an approach in which radiotherapy is delivered preoperatively if a substantial tumor downsizing is not achieved after upfront systemic chemotherapy or postoperatively if the pathologic CRM is involved. This single phase Ⅱ trial was aimed to evaluate the efficacy of FOLFOXIRI in treating patients with MRI-defined CRM-positive rectal cancer. All patients will receive the regimen every 2 weeks for 3 cycles. MRI of the pelvic will be performed after 3 cycles of chemotherapy to assess clinical response. If the tumor responds after 3 cycles of treatment, the patient will continue for another 3 cycles of treatment before surgery under the decision of MDT. On the contrary, if the tumor shows no response, radiotherapy will be given before operation. After surgery and pathologic CRM is not involved, 6 cycles of mFOLFOX6 will be given as adjuvant chemotherapy, otherwise postoperative radiotherapy will be given if the pathologic CRM is involved.
Interventions
DRUGFOLFOXIRI
irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
Sponsors
Guangxi Medical University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis of adenocarcinoma of the rectum * Age: 18-70years old * Signed informed consent; able to comply with study and/or followup procedures * Stage of the primary tumor may be determined by MRI as CRM positive * Tumor amenable to curative resection * Adequate bone marrow, hepatic and renal function as assessed by the following laboratory requirements conducted within 7 days of starting study treatment: * Leukocytes ≥ 3.0 x109/ L, absolute neutrophil count (ANC) ≥ 1.5 x109/ L, platelet count ≥ 100 x109/ L, hemoglobin (Hb) ≥ 9g/ dL. * Total bilirubin ≤1.5 x the upper limit of normal (ULN). * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 x ULN. * Alkaline phosphatase limit ≤ 5x ULN. * Amylase and lipase ≤ 1.5 x the ULN. * Serum creatinine ≤ 1.5 x the ULN. * No renal disease that would preclude study treatment or followup * ECOG status: 0～1
Exclusion criteria
* Hypersensitivity to fluorouracil, oxaliplatin or irinotecan. * Less than 4 weeks since prior participation in any investigational drug study * History of invasive rectal malignancy, regardless of disease free interval * Uncontrolled hypertension * Cardiovascular disease that would preclude study treatment or followup * Lack of upper gastrointestinal tract integrity or malabsorption syndrome，active upper gastrointestinal tract bleeding * Synchronous colon cancer * Pregnant or nursing * Other malignancy within the past 5 years except effectively treated squamous cell or basal cell skin cancer, melanoma in situ, carcinoma in situ of the cervix, or carcinoma in situ of the colon or rectum * No psychiatric or addictive disorders, or other conditions that, in the opinion of the investigator, would preclude study participation * patients refused to signed informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The rate of negative circumferential margin status | 30 days | Evaluation of the circumferential margin status (positive or negative) in the rectal specimen according international consensus (positive margin if tumor ≤ 1mm from circumferential margin) |
| The rate of R0 resection | 30 days | Evaluation of the resection margin status (positive or negative) in the rectal specimen |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The rate of tumor downstaging to stage 0 and stage Ⅰ | 2 years | Tumor downstaging from stage Ⅲ to pathologica complete response （stage 0） and stage Ⅰ |
| the local recurrence rate | 3 year | the rate of patients with local recurrence within 3 years |
| Recurrence free survival | 3 year | 3 years recurrence free survival of this group of patients |
| Reported Adverse events | 3 years | Number of patients with adverse events and severity according to NCI CTC 4.0 after treatment with this regimen |
Countries
China
Outcome results
None listed